AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29695500
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored rituximab regimen (500 mg infusion at randomisation, reinfusion based on CD19+B lymphocytes or ANCA levels)
Trial: 29695500
Drug: Fixed-schedule rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed-schedule rituximab regimen (500 mg infusion on days 0 and 14, then at 6, 12, and 18 months)
Trial: 24118023
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg day(-1) for 4 weeks
Trial: 24118023
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg day(-1) for 4 weeks
Trial: 24118023
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg day(-1) for 4 weeks
Trial: 12578924
Drug: Healthy control
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy control group (no treatment)
Trial: 18521686
Drug: Cytoreduction followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytoreduction followed by hyperthermic intraperitoneal chemotherapy (HIPEC) and systemic chemotherapy
Trial: 18521686
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy alone (Control)
Trial: 10048613
Drug: rHuEPO (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (300 IU/kg three times a week s.c.) and oral iron (ferrofumarate, 6 mg of iron/kg per day)
Trial: 10048613
Drug: rHuEPO (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (300 IU/kg three times a week s.c.) and intramuscular iron (ferroxypolymaltose, once 12 mg of iron/kg weekly)
Trial: 10048613
Drug: Intramuscular iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular iron (ferroxypolymaltose, once 12 mg of iron/kg weekly) without rHuEPO
Trial: 375461
Drug: Atropine methonitrate
RxNorm normalized name: Atropine methonitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine methonitrate 2 mg
Trial: 375461
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of salbutamol and atropine methonitrate
Trial: 27354046
Drug: Intravenous procainamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous procainamide (10 mg/kg/20 min)
Trial: 27354046
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (5 mg/kg/20 min)
Trial: 27354046
Drug: Intravenous procainamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous procainamide (10 mg/kg/20 min) in patients with structural heart disease
Trial: 27354046
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (5 mg/kg/20 min) in patients with structural heart disease
Trial: 2578352
Drug: Running under
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Running under hot conditions (rectal temperature increase averaging 2.3 degrees C)
Trial: 2578352
Drug: Running with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Running with additional cooling (rectal temperature rise reduced to an average of 1.0 degree C)
Trial: 37045
Drug: Dexchlorpheniramine 4
RxNorm normalized name: dexchlorpheniramine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexchlorpheniramine 4 mg
Trial: 18612151
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus chemotherapy (paclitaxel plus carboplatin)
Trial: 15695472
Drug: Polarity Therapy
RxNorm normalized name: Adlarity
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polarity Therapy (PT) treatments (1 or 2 treatments)
Trial: 15695472
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PT treatments)
Trial: 12406667
Drug: beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beclomethasone dipropionate bid (800 mcg) via jet nebulizer
Trial: 12406667
Drug: beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beclomethasone dipropionate bid (800 mcg) via ultrasonic nebulizer
Trial: 10427579
Drug: Clinical pharmacist
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacist participation in daily ward rounds, soliciting information, and reviewing charts
Trial: 8908382
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4.6 g n‐3 fatty acids/day)
Trial: 2057245
Drug: Survanta (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survanta (100 mg of phospholipids/kg)
Trial: 8950450
Drug: Metallic implants
RxNorm normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metallic implants
Trial: 26803913
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg/day, 250 mg twice daily) added to lipid-lowering therapy
Trial: 26803913
Drug: Lipid-lowering agents
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering agents (control group)
Trial: 20489088
Drug: Sequential scanning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential scanning mode
Trial: 17548203
Drug: Cilostazol (100mg)
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol (100mg) twice daily orally
Trial: 10604491
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg losartan once daily
Trial: 7828295
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg losartan once daily
Trial: 7828295
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg losartan once daily
Trial: 7828295
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg losartan once daily
Trial: 7828295
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg losartan once daily after 12 weeks
Trial: 7828295
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg losartan once daily after 12 weeks
Trial: 7828295
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg losartan once daily after 12 weeks
Trial: 7828295
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (all doses)
Trial: 7049364
Drug: CCNU (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCNU (130 mg/m2 every 6 weeks) + dexamethasone (4‐20 mg daily)
Trial: 7049364
Drug: CCNU (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCNU (130 mg/m2 every 6 weeks)
Trial: 7049364
Drug: VM‐26 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM‐26 (100 mg/m2) + CCNU (130 mg/m2 every 6 weeks)
Trial: 7049364
Drug: Procarbazine (3‐week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procarbazine (3‐week courses of 150 mg/m2/day)
Trial: 30892603
Drug: PUVA induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA induction regimen (oral 8-methoxypsoralen followed by UV-A exposure 2 times per week for 12 to 24 weeks)
Trial: 30892603
Drug: PUVA maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA maintenance treatment (14 total exposures for 9 months)
Trial: 25417709
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral conjugated equine estrogen (oCEE, 0.45 mg)
Trial: 25417709
Drug: Weekly transdermal
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly transdermal 17β‐estradiol (tE2, 50 μg)
Trial: 23884353
Drug: AMG145 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 70 mg every 2 weeks
Trial: 23884353
Drug: AMG145 105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 105 mg every 2 weeks
Trial: 23884353
Drug: AMG145 140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 140 mg every 2 weeks
Trial: 23884353
Drug: AMG145 280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 280 mg every 4 weeks
Trial: 23884353
Drug: AMG145 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 350 mg every 4 weeks
Trial: 23884353
Drug: AMG145 420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG145 420 mg every 4 weeks
Trial: 21091270
Drug: Olmesartan (O)
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (O) 10 mg once daily, with potential dose increase to 40 mg
Trial: 21091270
Drug: Olmesartan (O)
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (O) 10 mg once daily
Trial: 21091270
Drug: Ramipril (R)
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril (R) 2.5 mg once daily, with potential dose increase to 10 mg
Trial: 17482847
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (n=9)
Trial: 17482847
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (n=7)
Trial: 9551595
Drug: low-dose or
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose or standard-dose weight-adjusted heparin
Trial: 24980
Drug: Fosazepam 60
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosazepam 60 mg
Trial: 30981954
Drug: Oxfendazole, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxfendazole, administered as multiple oral doses, specific dosage not mentioned.
Trial: 15471149
Drug: Biventricular stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biventricular stimulation (cardiac resynchronization therapy)
Trial: 7831649
Drug: Fragmin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin (low molecular weight heparin) administered subcutaneously once daily at a fixed dose of 200 IU anti-factor Xa/kg
Trial: 7831649
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of unfractionated heparin (UFH)
Trial: 2956864
Drug: Enoximone 1
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 1 mg/kg
Trial: 2956864
Drug: Enoximone 2
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone 2 mg/kg
Trial: 30187734
Drug: IBA 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBA 0.25 mg L‐1 and kinetin 1 mg L‐1
Trial: 30187734
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (no added NAA and IBA)
Trial: 18803795
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (pill)
Trial: 12684357
Drug: Commercial weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial weight loss program (n = 211) consisting of a food plan, activity plan, and cognitive restructuring behavior modification plan, delivered at weekly meetings.
Trial: 1549990
Drug: rTPA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTPA (100 mg over 3 hours)
Trial: 3698694
Drug: Incentive spirometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive spirometry (encouraged by a specialized respiratory physiotherapist to breathe deeply for five minutes hourly, 12 times daily, for three postoperative days)
Trial: 20921834
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% in water (D5W) injection before catheter placement
Trial: 19218250
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection (Control)
Trial: 18514618
Drug: Special oral
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special oral nutritional mixture of amino acids (AAs) 4 g twice daily (n = 43)
Trial: 16781338
Drug: Topical minocycline
RxNorm normalized name: minocycline Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minocycline (1.0 mg in bioresorbable polyglycolide‐co‐dl‐lactide [PGLA] sustained‐release microspheres)
Trial: 16781338
Drug: Topical minocycline
RxNorm normalized name: minocycline Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minocycline
Trial: 14585449
Drug: Antacid (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (Group 1)
Trial: 14585449
Drug: Antacid +
RxNorm normalized name: Walgreens Antacid + Anti-Gas Liquid (Mint)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid + Donnatal (Group 2)
Trial: 14585449
Drug: Antacid +
RxNorm normalized name: Walgreens Antacid + Anti-Gas Liquid (Mint)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid + Donnatal + viscous lidocaine (Group 3)
Trial: 9558049
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg/day)
Trial: 1578954
Drug: BHAC-DMP +
RxNorm normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHAC-DMP + VCR 0.35 mg/m2 on days 1-4
Trial: 1578954
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy of 12 courses
Trial: 1578954
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy of 4 courses
Trial: 27869485
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (90-min sessions, twice a week for 8 weeks)
Trial: 19249048
Drug: 800 microg
RxNorm normalized name: Fentanyl 800 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 microg of rectal misoprostol
Trial: 19249048
Drug: 5 IU
RxNorm normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU of intravenous oxytocin
Trial: 9523811
Drug: 0.45 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/kg rocuronium
Trial: 9235005
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg atracurium
Trial: 9662821
Drug: Erythromycin, 500
RxNorm normalized name: Erythromycin, 500 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 500 mg orally twice a day for 15-14 days
Trial: 9662821
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of recombinant alpha 2‐interferon with complex immunoglobulin preparation (CTP), vaginal suppositories containing 300 mg of CTP and intravaginal application of 15(2)-30 ml of solution containing 2.0 x 10(6) I.U. of recombinant alpha 2‐interferon
Trial: 9662821
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of recombinant alpha 2‐interferon with complex immunoglobulin preparation (CTP)
Trial: 24134550
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and Pioglitazone
Trial: 10884648
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion at 1 microg. kg(‐1). min(‐1) starting 10 minutes before cardiopulmonary bypass and maintained for 4 hours
Trial: 9527094
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion
Trial: 9605251
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of antenatal antibiotic therapy
Trial: 2873967
Drug: Oral astemizole
RxNorm normalized name: Astemizole
DrugBank: Astemizole (DB00637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral astemizole (30 mg during the first week, then 10 mg for the rest of the study period)
Trial: 2873967
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium cromoglycate (2%, administered 6-times daily intranasally and 4-times daily in the eyes)
Trial: 28161387
Drug: Intranasal vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal vasopressin (20IU)
Trial: 23451243
Drug: Propranolol (PROP)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (PROP) 80 mg administered 60 minutes prior to stress exposure
Trial: 21336835
Drug: Carbetocin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (100 μg, single intramuscular dose)
Trial: 21336835
Drug: Syntometrine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syntometrine (single intramuscular dose)
Trial: 19172538
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (0.625 mg) plus methyl-testosterone (1.25 mg) and micronised progesterone (100 mg)
Trial: 16246545
Drug: CPT‐11 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 administered at 180 mg/m2 on day 1, by 1‐h infusion (Arm A)
Trial: 16246545
Drug: 6‐h sinusoidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐h sinusoidal infusion of CPT‐11 with peak timing at 5:00 a.m. (Arm B)
Trial: 14677160
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: actual LPLT (5 minutes, 3 J total dose + exercise)
Trial: 14677160
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: actual LPLT (3 minutes, 2 J total dose + exercise)
Trial: 2982882
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with vincristin, methotrexate, and cyclophosphamide
Trial: 2982882
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with vincristin, methotrexate, and cyclophosphamide plus systemic immunotherapy with Propionibacterium granulosum strain KP-45
Trial: 29059068
Drug: Armeo robotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armeo robotic therapy (12 weeks, 45 min/session, 3 days/week)
Trial: 29059068
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (12 weeks)
Trial: 22469559
Drug: Bortezomib dose
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib dose intensity
Trial: 8141435
Drug: Theophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5 mg/kg body weight intravenous infusion over 20 min, followed by 1 mg/kg per hour)
Trial: 8141435
Drug: Theophylline at
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline at subtherapeutic concentrations (5 micrograms/ml)
Trial: 31296328
Drug: Postoperative rectal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative rectal tube for 5 days (Group A)
Trial: 31296328
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative rectal tube (Group B)
Trial: 21511276
Drug: LY2216684 6-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2216684 6-18 mg once daily
Trial: 17956931
Drug: Minimal Intervention
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Intervention Bibliotherapy Treatment (MIT)
Trial: 14615738
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A therapy (administered intramuscularly on days 1, 3, and 7)
Trial: 10979640
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg daily for 12 weeks
Trial: 10979640
Drug: Losartan 25
RxNorm normalized name: LOSARTAN 25MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 25 mg daily for 12 weeks